On August 5, 2025, the Department of Health and Human Services canceled 22 mRNA vaccine projects valued at roughly $500 million. One year later, the FDA approved mFLUSIVA, the first mRNA influenza vaccine licensed in the United States. The actions occurred amid disputed claims about mRNA effectiveness against respiratory infections and low adult flu vaccination rates below 50 percent during the 2025-2026 season.